 |
5 Products |  |
33 Diseases | | 5 Products |
|
1369 Trials |  |
5508 News |  |
| «12...3435363738394041424344...4748» |
- etoposide IV / Generic mfg., Focus V (anlotinib) / Advenchen, Sino Biopharm
[VIRTUAL] Safety and efficacy of anlotinib combined with etoposide and platinum-based regimens in the first-line treatment of extensive-stage small cell lung cancer (On-Demand) - Jul 24, 2020 - Abstract #ESMO2020ESMO_2547;
P2
Funding: Has not received any funding. Clinical trial identification: The trial protocol number is NCT03841136 and the release date is March 26th, 2019.
- Focus V (anlotinib) / Advenchen, Sino Biopharm
[VIRTUAL] Efficacy and safety analysis of EP / EC regimen combined with first-line anlotinib hydrochloride in the treatment of extensive small cell lung cancer: Results from a phase II single-arm trial (On-Demand) - Jul 24, 2020 - Abstract #ESMO2020ESMO_2543;
Legal entity responsible for the study: Tiandong Kong. Funding: Has not received any funding.
- etoposide IV / Generic mfg., Focus V (anlotinib) / Advenchen, Sino Biopharm
[VIRTUAL] Anlotinib combined with etoposide as maintenance treatment in extensive-stage small cell lung cancer (ES-SCLC): A single-arm, prospective phase II study (On-Demand) - Jul 24, 2020 - Abstract #ESMO2020ESMO_2541;
Legal entity responsible for the study: Bo Shen. Funding: Chia Tai Tianqing Pharmaceutical Group Co., LTD.
- Focus V (anlotinib) / Advenchen, Sino Biopharm
[VIRTUAL] Effect of anlotinib in advanced small cell lung cancer (SCLC) patients with liver metastases: A subgroup analysis from a randomized, double-blind phase II trial (ALTER 1202) (On-Demand) - Jul 24, 2020 - Abstract #ESMO2020ESMO_2537;
P2
Funding: Chia Tai Tianqing Pharm co., Ltd. Clinical trial identification: NCT03059797.
- Focus V (anlotinib) / Advenchen, Sino Biopharm
[VIRTUAL] Effect of anlotinib in advanced small cell lung cancer patients with pleural metastases/pleural effusion: A subgroup analysis from a randomized, double-blind phase II trial (ALTER1202) (On-Demand) - Jul 24, 2020 - Abstract #ESMO2020ESMO_2533;
P2
Funding: Has not received any funding. Clinical trial identification: NCT03059797.
- Focus V (anlotinib) / Advenchen, Sino Biopharm, irinotecan / Generic mfg.
[VIRTUAL] Dynamic changes in quality of life and Q-TWiST analysis for Ewing sarcoma patients following anlotinib and irinotecan: A combination of phase Ib and II trial (On-Demand) - Jul 24, 2020 - Abstract #ESMO2020ESMO_2400;
P1/2
Funding: Has not received any funding. Clinical trial identification: NCT03416517.
- cisplatin / Generic mfg., paclitaxel / Generic mfg., Focus V (anlotinib) / Advenchen, Sino Biopharm
[VIRTUAL] Paclitaxel and cisplatin combined with anlotinib as first line regimen for advanced esophageal squamous cell carcinoma (ESCC): A single-arm, multicentre open-label phase II clinical trial (On-Demand) - Jul 24, 2020 - Abstract #ESMO2020ESMO_2224;
P2
LTD (CTTQ). Clinical trial identification: NCT04063683.
- Focus V (anlotinib) / Advenchen, Sino Biopharm
[VIRTUAL] Anlotinib combined with whole brain radiation therapy (WBRT) for advanced non-small cell lung cancer with multiple brain metastases: An open-label, single-arm phase II trial (On-Demand) - Jul 24, 2020 - Abstract #ESMO2020ESMO_2166;
Legal entity responsible for the study: Xiangzhi Zhu. Funding: Has not received any funding.
- Focus V (anlotinib) / Advenchen, Sino Biopharm, docetaxel / Generic mfg.
[VIRTUAL] Anlotinib combination with docetaxol for patients with previously treated advanced non-small cell lung cancer: A phase II, single-arm trial (On-Demand) - Jul 24, 2020 - Abstract #ESMO2020ESMO_2156;
Funding: Has not received any funding. Clinical trial identification: ChiCTR1800020011.
- Conmana (icotinib) / Betta, Focus V (anlotinib) / Advenchen, Sino Biopharm
[VIRTUAL] Anlotinib combined with icotinib provides a promising first-line treatment option for EGFR positive NSCLC patients harboring concomitant mutations: Exploratory analysis of the ALTER-L004 study (On-Demand) - Jul 24, 2020 - Abstract #ESMO2020ESMO_2122;
P2
Funding: Has not received any funding. Clinical trial identification: NCT03736837, December 1, 2018.
- Focus V (anlotinib) / Advenchen, Sino Biopharm
[VIRTUAL] ALTER-H-004: A phase II study of anlotinib combined with TACE as adjuvant therapy in hepatocellular carcinoma patients at high risk of post-surgery recurrence (On-Demand) - Jul 24, 2020 - Abstract #ESMO2020ESMO_1825;
P2
Funding: Has not received any funding. Clinical trial identification: NCT04213118.
- Focus V (anlotinib) / Advenchen, Sino Biopharm
[VIRTUAL] Anlotinib in patients with recurrent or metastatic nasopharyngeal carcinoma: An interim analysis of a phase II clinical trial (On-Demand) - Jul 24, 2020 - Abstract #ESMO2020ESMO_1736;
P2
81672686). Clinical trial identification: NCT03906058; April 5th 2019.
- Focus V (anlotinib) / Advenchen, Sino Biopharm, APL-502 / Apollomics
[VIRTUAL] A phase Ib study of TQB2450 in combination with anlotinib in patients with advanced solid tumour (On-Demand) - Jul 24, 2020 - Abstract #ESMO2020ESMO_1618;
P1
Funding: Has not received any funding. Clinical trial identification: NCT03897283.
- | Loqtorzi (toripalimab-tpzi) / Shanghai Junshi Biosci, Coherus Biosci, Tagrisso (osimertinib) / AstraZeneca, Focus V (anlotinib) / Advenchen, Sino Biopharm
Enrollment open: Efficacy and Safety of Toripalimab (JS001) Combined With Pemetrexed and Anlotinib for Patients With T790M Positive Non-Small Cell Lung Cancer After Osimertinib Resistance (clinicaltrials.gov) - Jul 22, 2020
P2, N=60, Recruiting, Sponsor: Guangzhou Institute of Respiratory Disease
Clinical trial identification: NCT03897283. Not yet recruiting --> Recruiting
- Tyvyt (sintilimab) / Eli Lilly, Focus V (anlotinib) / Advenchen, Sino Biopharm
[VIRTUAL] A phase II study of sintilimab plus anlotinib for Chinese patients (pts) with persistent, recurrent, or metastatic cervical cancer (CC) (On-Demand) - Jul 21, 2020 - Abstract #ESMO2020ESMO_1115;
Funding: Has not received any funding. Clinical trial identification: ChiCTR1900023015.
- pemetrexed / Generic mfg., Focus V (anlotinib) / Advenchen, Sino Biopharm
[VIRTUAL] Phase II study of anlotinib plus pemetrexed for platinum-resistant epithelial ovarian cancer (On-Demand) - Jul 21, 2020 - Abstract #ESMO2020ESMO_1091;
Funding: Beijing Medical and Health Found. Clinical trial identification: ChiCTR1800018192.
- Focus V (anlotinib) / Advenchen, Sino Biopharm
[VIRTUAL] Efficacy and safety of anlotinib combined with CAPEOX in first-line treatment of patients with RAS and BRAF wild-type unresectable metastatic colorectal cancer - A single-arm, multi-center, phase II study (ALTER-C-002 trial) (On-Demand) - Jul 21, 2020 - Abstract #ESMO2020ESMO_764;
P2
Funding: Has not received any funding. Clinical trial identification: NCT04080843.
- Avastin (bevacizumab) / Roche
[VIRTUAL] Targeting Angiomotin-p130 reverse resistance to antiangiogenic therapies in breast cancer by inhibition of vasculogenic mimicry (On-Demand) - Jul 21, 2020 - Abstract #ESMO2020ESMO_352;
Legal entity responsible for the study: Yanwei Shen. Funding: Has not received any funding.
- | Focus V (anlotinib) / Advenchen, Sino Biopharm
Journal: Salvage treatment with anlotinib for advanced non-small cell lung cancer. (Pubmed Central) - Jul 21, 2020
Anlotinib, which is well tolerated, plays a significant role in the salvage treatment of advanced NSCLC. Patients with advanced NSCLC with an ECOG PS of 0-1 and no brain metastases achieved longer PFS following anlotinib salvage treatment.
- ||| AL2846 / Advenchen, Sino Biopharm
Enrollment open, Trial initiation date, Metastases: A Study of AL2846 Capsule Combined With Standard Chemotherapy Regimen in Subjects With Advanced Colorectal Cancer (clinicaltrials.gov) - Jul 20, 2020
P1/2, N=56, Recruiting, Sponsor: Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Patients with advanced NSCLC with an ECOG PS of 0-1 and no brain metastases achieved longer PFS following anlotinib salvage treatment. Not yet recruiting --> Recruiting | Initiation date: Apr 2020 --> Jul 2020
- | AiTan (rivoceranib) / HLB Bio Group, AiRuiKa (camrelizumab) / HLB Bio Group
New P1/2 trial, Combination therapy: CARD: Camrelizumab in Combination With Apatinib in Refractory and Relapsed DLBCL (clinicaltrials.gov) - Jul 20, 2020
P1/2, N=33, Not yet recruiting, Sponsor: Huiqiang Huang
- |||||| AiTan (rivoceranib) / HLB Bio Group
Enrollment open, Trial completion date, Metastases: A Phase 3 Study Comparing Carelizumab Plus Nab-paclitaxel and Apatinib, Carelizumab Plus Nab-paclitaxel, and Nab-paclitaxel in Patients With Advanced Triple Negative Breast Cancer. (clinicaltrials.gov) - Jul 16, 2020
P3, N=780, Recruiting, Sponsor: Jiangsu HengRui Medicine Co., Ltd.
Not yet recruiting --> Recruiting | Initiation date: Apr 2020 --> Jul 2020 Not yet recruiting --> Recruiting | Trial completion date: Nov 2024 --> Jan 2024
- Focus V (anlotinib) / Advenchen, Sino Biopharm
[VIRTUAL] Short-term efficacy of advanced NSCLC patients receiving anlotinib hydrochloride as the first and second-line treatment (Pre-congress content) - Jul 15, 2020 - Abstract #ERS2020ERS_2347;
Not yet recruiting --> Recruiting | Trial completion date: Nov 2024 --> Jan 2024 Among the patients in this trial, Anlotinib showed promising efficacy for patients who never had opportunity to accept targeted therapy and did not tolerate chemotherapy.
- | Focus V (anlotinib) / Advenchen, Sino Biopharm
New trial, Metastases: TC Plus PD-1 Inhibitors Combined With Anlotinib for Advanced Advanced Esophageal Cancer (clinicaltrials.gov) - Jul 14, 2020
P=N/A, N=90, Not yet recruiting, Sponsor: Dong Wang
- | AL-034 / J&J
Trial initiation date, Metastases: TQA3334-?-02: A Study to Evaluate the Tolerance, Pharmacokinetics and Efficacy of TQ-A3334 Tablets (clinicaltrials.gov) - Jul 7, 2020
P1/2, N=40, Recruiting, Sponsor: Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Among the patients in this trial, Anlotinib showed promising efficacy for patients who never had opportunity to accept targeted therapy and did not tolerate chemotherapy. Initiation date: Mar 2020 --> Jul 2020
- Focus V (anlotinib) / Advenchen, Sino Biopharm
[VIRTUAL] Anlotinib Attenuates Pulmonary Fibrosis by Inhibiting Glycolytic Reprogramming (ATS 2020 Virtual) - Jul 6, 2020 - Abstract #ATSI2020ATS-I_4933;
Our results demonstrate that the anti-fibrotic effect of anlotinib is considered to be associated with the inhibition of glycolytic reprogramming. Since anlotinib has both preventive and therapeutic effects on pulmonary fibrosis, anlotinib has potential as a novel therapeutic treatment for IPF.
- | Focus V (anlotinib) / Advenchen, Sino Biopharmaceutical
Journal: Anlotinib Suppresses Colorectal Cancer Proliferation and Angiogenesis via Inhibition of AKT/ERK Signaling Cascade. (Pubmed Central) - Jul 3, 2020
Furthermore, anlotinib was able to inhibit the activation of VEGFR-2/AKT and FGFR, PDGFRβ and their downstream signaling ERK. The findings of the present study suggested that anlotinib suppressed cell proliferation and angiogenesis via inhibition of AKT/ERK signaling pathway in colorectal cancer and could be a novel therapeutic strategy for treatment of CRC.
- |||||| Focus V (anlotinib) / Advenchen, Sino Biopharm, benmelstobart (APL-502) / Apollomics
Enrollment open, PD(L)-1 Biomarker, IO biomarker, Metastases: TQB2450-III-05: A Study of TQB2450 in Subjects With Stage III Non-Small Cell Lung Cancer(NSCLC) (clinicaltrials.gov) - Jun 30, 2020
P3, N=315, Recruiting, Sponsor: Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
The findings of the present study suggested that anlotinib suppressed cell proliferation and angiogenesis via inhibition of AKT/ERK signaling pathway in colorectal cancer and could be a novel therapeutic strategy for treatment of CRC. Not yet recruiting --> Recruiting
- || Focus V (anlotinib) / Advenchen, Sino Biopharm, benmelstobart (APL-502) / Apollomics
Enrollment open: ACTION: A Study of TQB2450 Combined With Anlotinib in Subjects With Gynecological Cancer (clinicaltrials.gov) - Jun 30, 2020
P1/2, N=30, Recruiting, Sponsor: Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Not yet recruiting --> Recruiting Not yet recruiting --> Recruiting
- | Focus V (anlotinib) / Advenchen, Sino Biopharm
New P2 trial: Combination Chemotherapy With or Without Anlotinib in the Maintenance Treatment of Non-Squamous Non-Small Cell Lung Cancer. (clinicaltrials.gov) - Jun 30, 2020
P2, N=90, Not yet recruiting, Sponsor: The First Affiliated Hospital with Nanjing Medical University
- | Focus V (anlotinib) / Advenchen, Sino Biopharm
New P2 trial, Metastases: Oral Etoposide Combined With Anlotinib in Advanced Triple Negative Breast Cancer (clinicaltrials.gov) - Jun 29, 2020
P2, N=100, Not yet recruiting, Sponsor: Chinese Academy of Medical Sciences
- | Avastin (bevacizumab) / Roche
Journal: Bevacizumab promotes active biological behaviors of human umbilical vein endothelial cells by activating TGFβ1 pathways via off-VEGF signaling. (Pubmed Central) - Jun 27, 2020
Bevacizumab promotes migration and tube formation of HUVECs via activation of the TGFβ1 pathway and upregulation of CD105 expression. Anlotinib reverses the effects of bevacizumab by inhibiting the above signals.
- | AiTan (rivoceranib) / HLB Bio Group
Trial primary completion date, Tumor mutational burden, Metastases: A Study to Evaluate Apatinib (Also Known as Rivoceranib) Plus Nivolumab in Participants With Unresectable or Metastatic Cancer (clinicaltrials.gov) - Jun 23, 2020
P1, N=30, Active, not recruiting, Sponsor: Elevar Therapeutics
Anlotinib reverses the effects of bevacizumab by inhibiting the above signals. Trial primary completion date: Jun 2020 --> Sep 2020
- ||| Anniko (penpulimab) / Akesobio, Sino Biopharm, Focus V (anlotinib) / Advenchen, Sino Biopharm
Enrollment open, Trial initiation date, Metastases: ALTN-AK105-II-01: A Study of Anlotinib and AK105 Injection in Subjects With Advanced Head, Neck and Chest Cancer (clinicaltrials.gov) - Jun 22, 2020
P2, N=140, Recruiting, Sponsor: Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Trial primary completion date: Jun 2020 --> Sep 2020 Not yet recruiting --> Recruiting | Initiation date: Jan 2020 --> May 2020
- | Focus V (anlotinib) / Advenchen, Sino Biopharmaceutical
Journal: Anlotinib Exerts Anti-Cancer Effects on KRAS-Mutated Lung Cancer Cell Through Suppressing the MEK/ERK Pathway. (Pubmed Central) - Jun 19, 2020
Anlotinib inhibits the growth of KRAS mutant lung cancer cells partly via the suppression of the MEK/ERK pathway. Our findings provide novel insights into treating recalcitrant KRAS mutated NSCLC.
- || Focus V (anlotinib) / Advenchen, Sino Biopharmaceutical
Clinical, Journal: A Trial of the Safety and Efficacy of Chemotherapy Plus Anlotinib vs Chemotherapy Alone as Second- or Third-Line Salvage Treatment for Advanced Non-Small Cell Lung Cancer. (Pubmed Central) - Jun 19, 2020
In general, most toxicity was limited to grade I or II, well tolerated and controlled. Our study suggests that anlotinib combined with chemotherapy may be an effective and well-tolerated treatment for advanced NSCLC in patients who fail first- or second-line therapy.
- |||||||||| Focus V (anlotinib) / Advenchen, Sino Biopharm
New P3 trial, Metastases: A Efficacy and Safety Study of Anlotinib Hydrochloride Capsule Combined With Chemotherapy Versus Placebo Combined With Chemotherapy as First-line Treatment in Subjects With Advanced Non-squamous Cell Non-small Cell Lung Cancer (clinicaltrials.gov) - Jun 18, 2020
P3, N=369, Recruiting, Sponsor: Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
- | Tagrisso (osimertinib) / AstraZeneca, Focus V (anlotinib) / Advenchen, Sino Biopharm
New P2 trial: Osimertinib Combined With Anlotinib in EGFR T790M Mutated NSCLC Patients With Progression on Osimertinib Treatment (clinicaltrials.gov) - Jun 18, 2020
P2, N=30, Not yet recruiting, Sponsor: First Affiliated Hospital of Zhejiang University
- || etoposide IV / Generic mfg., Focus V (anlotinib) / Advenchen, Sino Biopharmaceutical
Clinical, Journal: Anlotinib combined with etoposide for platinum-resistant recurrent ovarian cancer: A case report. (Pubmed Central) - Jun 18, 2020
Our study suggests that anlotinib combined with chemotherapy may be an effective and well-tolerated treatment for advanced NSCLC in patients who fail first- or second-line therapy. Our case suggests that oral treatment of anlotinib combined with etoposide which is acceptable and convenient, may be an additional option for the management of platinum-resistant ovarian cancer.
- ||| Anniko (penpulimab) / Akesobio, Sino Biopharm, Focus V (anlotinib) / Advenchen, Sino Biopharm
Enrollment open, Trial initiation date: ALTN-AK105-II-02: A Study of Anlotinib and AK105 Injection in Subjects With Gastrointestinal Tumors, Urinary System Tumors, Neuroendocrine Tumors (clinicaltrials.gov) - Jun 17, 2020
P2, N=150, Recruiting, Sponsor: Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Our case suggests that oral treatment of anlotinib combined with etoposide which is acceptable and convenient, may be an additional option for the management of platinum-resistant ovarian cancer. Not yet recruiting --> Recruiting | Initiation date: Jan 2020 --> Jun 2020
- | AiTan (rivoceranib) / HLB Bio Group, AiRuiKa (camrelizumab) / HLB Bio Group
New P2 trial, Metastases: Camrelizumab Combined With Apatinib Mesylate and Standard Chemotherapy (Pemetrixed + Carboplatin) in Patients With Tyrosine Kinase Inhibitor Failure in ALK-positive Advanced NSCLC (clinicaltrials.gov) - Jun 11, 2020
P2, N=59, Not yet recruiting, Sponsor: The First Affiliated Hospital of Xiamen University
- || Focus V (anlotinib) / Advenchen, Sino Biopharmaceutical
Clinical, Journal, Real-World Evidence: Efficacy and Safety of Anlotinib in Advanced Non-Small Cell Lung Cancer: A Real-World Study. (Pubmed Central) - Jun 6, 2020
Anlotinib was well tolerated and effective in patients with advanced NSCLC in real-world conditions. Patients with ECOG PS ≤1 or no liver metastases have longer PFS and OS.
- | bleomycin / Generic mfg., BMS, Focus V (anlotinib) / Advenchen, Sino Biopharmaceutical
Biomarker, Journal: Anlotinib attenuated bleomycin-induced pulmonary fibrosis via the TGF-β1 signalling pathway. (Pubmed Central) - Jun 4, 2020
Patients with ECOG PS ≤1 or no liver metastases have longer PFS and OS. In summary, the results suggest that anlotinib-mediated suppression of pulmonary fibrosis is related to the inhibition of TGF-β1 signalling pathway.
- || fluorouracil / Generic mfg., Focus V (anlotinib) / Advenchen, Sino Biopharmaceutical
Clinical, P2 data, Journal: Anlotinib Combined with S-1 in the Third-Line Treatment of Stage IV Non-Small Cell Lung Cancer: Study Protocol for Phase II Clinical Trial. (Pubmed Central) - Jun 4, 2020
The expected outcome of this study is that anlotinib combined with S-1 has tolerable toxicity and better ORR than anlotinibmonotherapy. The results may indicate additional treatment options for patients with stage IV NSCLC.
- || Focus V (anlotinib) / Advenchen, Sino Biopharmaceutical
Clinical, Journal: Intervention of Vascular Dysplasia Caused by Different Mechanisms - Anlotinib for Right Lung Squamous Cell Carcinoma Combined with Thromboangiitis Obliterans: A Case Report and Literature Review (Pubmed Central) - Jun 4, 2020
Anlotinib effectively controlled the growth of NSCLC and improved TAO related symptoms. Anlotinib maybe normalize disordered growth of blood vessels through the VEGF signaling pathway, rather than simply inhibiting angiogenesis.
- ||| Focus V (anlotinib) / Advenchen, Sino Biopharmaceutical
The data with anlotinib over the last few years have looked quite promising over last few years, both in SCLC & NSCLC. I’d definitely keep a close eye on this agent. (Twitter) - May 30, 2020
- |||| Focus V (anlotinib) / Advenchen, Sino Biopharmaceutical
P2 data: #ASCO20 But hard to learn much from a single arm phase II for 1L #SCLC. Hopefully correlative studies done to guide development. Anlotinib has interesting potential: possible partner with chemo-IO? (Twitter) - May 29, 2020
- |||||| etoposide IV / Generic mfg., Focus V (anlotinib) / Advenchen, Sino Biopharmaceutical
Clinical: #ASCO20 Nice trial by Dr. Deng looking at platinum/etoposide plus anlotinib (VEGFR, FGFR, PDGFR TKI) in #SCLC showing tolerability and efficacy. ORR 78%, DCR 96%, mPFS 9.6m. #OncoAlert #LCSM (Twitter) - May 29, 2020
- ||||| Focus V (anlotinib) / Advenchen, Sino Biopharmaceutical
Clinical: #ASCO20 Report from ALTER 1202 study of anlotinib in #SCLC shows benefit to anlotinib over placebo in pts whose disease progressed within 3m of 2nd line therapy (a challenging group). Nice to see work from my friend from IMp133, Dr. Ying Chen! #OncoAlert #LCSM (Twitter) - May 29, 2020
- || Focus V (anlotinib) / Advenchen, Sino Biopharmaceutical
Clinical, P2 data, Journal: Anlotinib for Patients With Metastatic Renal Cell Carcinoma Previously Treated With One Vascular Endothelial Growth Factor Receptor-Tyrosine Kinase Inhibitor: A Phase 2 Trial. (Pubmed Central) - May 28, 2020
P2
Anlotinib showed promising efficacy as well as favorable safety as second-line treatment for patients with mRCC. Clinical Trial Registration: www.ClinicalTrials.gov, identifier: NCT02072044.